Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 41 to 50 of 220 total matches.
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication ...
The FDA has approved the oral kinase inhibitor
quizartinib (Vanflyta – Daiichi Sankyo) for use
in combination with standard cytarabine and
anthracycline induction and cytarabine consolidation,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication (ITD)-positive, newly-diagnosed
acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 doi:10.58347/tml.2023.1687d | Show Introduction Hide Introduction
Drugs for Breast Cancer
Treatment Guidelines from The Medical Letter • Jan 01, 2005 (Issue 29)
and
their adverse effects begins on page 3.
ADJUVANT THERAPY
CHEMOTHERAPY — Adjuvant combination
chemotherapy ...
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
. Patients were randomized to receive
tebentafusp or investigator-selected chemotherapy
(pembrolizumab ...
The FDA has approved tebentafusp-tebn (Kimmtrak –
Immunocore), a first-in-class bispecific gp100
peptide-HLA-directed CD3 T-cell engager, for
treatment of HLA-A*02:01-positive unresectable or
metastatic uveal melanoma in adults.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e107-8 doi:10.58347/tml.2024.1705f | Show Introduction Hide Introduction
Plerixafor (Mozobil)
The Medical Letter on Drugs and Therapeutics • Apr 05, 2010 (Issue 1335)
chemotherapy with autologous stem cell rescue.
STANDARD TREATMENT — High-dose chemotherapy can overcome ...
The FDA has approved plerixafor (Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen) to mobilize peripheral blood stem cells in adults with multiple myeloma or non-Hodgkin’s lymphoma before high-dose chemotherapy with autologous stem cell rescue.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
conjugate to become available in
the US.
Standard Treatment – Sequential single-agent
chemotherapy ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Erythropoietin Safety Concerns
The Medical Letter on Drugs and Therapeutics • May 07, 2007 (Issue 1260)
chemotherapy have found an increased
risk of thromboembolic events, disease progression and
mortality ...
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
)-negative, high-risk
early breast cancer who received prior neoadjuvant
or adjuvant chemotherapy.1 It had ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone or prednisolone for treatment of adults
with deleterious or suspected deleterious BRCA-mutated
(BRCAm) metastatic castration-resistant
prostate cancer (mCRPC). Olaparib was previously
approved by the FDA for treatment of adults with
deleterious or suspected deleterious germline or
somatic homologous recombinant repair (HRR) genemutated
mCRPC who progressed on prior treatment
with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7 doi:10.58347/tml.2023.1679g | Show Introduction Hide Introduction
Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET
bispecific antibody, has received accelerated
approval from the FDA for IV treatment of locally
advanced or metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion mutations in adults whose
disease has progressed on or after platinum-based
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication.
Accelerated approval of the drug was based on the
overall response rate and duration of response.
Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005 (Issue 1205)
for patients who have
failed at least one prior chemotherapy regimen.
Cetuximab (Erbitux), the only ...
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
Zarxio - A Filgrastim Biosimilar
The Medical Letter on Drugs and Therapeutics • Mar 14, 2016 (Issue 1490)
chemotherapy treatment of
patients with acute myeloid leukemia
▶ Reduce the duration of neutropenia ...
The FDA has approved filgrastim-sndz (Zarxio –
Sandoz), a biosimilar of the recombinant human
granulocyte colony-stimulating factor filgrastim
(G-CSF; Neupogen), which has been available in the
US since 1991. Zarxio is the first biosimilar product to
be approved in the US; it has been available in Europe
as Zarzio since 2009.